bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
Authors: André Fabrice , Bachelot Thomas , Campone Mario , Dalenc Florence , Perez-Garcia Jose M. , Hurvitz Sara A. , Turner Nicholas , Rugo Hope , Smith John W. , Deudon Stephanie , Shi Michael , Zhang Yong , Kay Andrea , Graus Porta Diana , Yovine Alejandro , Baselga José
Published: April 2023

PDF file - 20K, Dovitinib effectively targets FGFR1 in vivo. FGF23 levels were measured from plasma taken at baseline and during dovitinib treatment in 18, 33, and 20 patients from the FGFR1+/HR+, FGFR1-/HR+, and FGFR1-/HR- patient groups, respectively. Error bars represent the 95% confidence intervals.
Supplementary Table 1 from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization
Authors: Niesvizky Ruben , Mark Tomer M. , Ward Maureen , Jayabalan David S. , Pearse Roger N. , Manco Megan , Stern Jessica , Christos Paul J. , Mathews Lena , Shore Tsiporah B. , Zafar Faiza , Pekle Karen , Xiang Zhaoying , Ely Scott , Skerret Donna , Chen-Kiang Selina , Coleman Morton , Lane Maureen E.
Published: April 2023

PDF file - 59K, Responses rates after DoVeD induction, bortezomib- or non-bortezomib-based mobilization, and SCT.
Supplementary Figure 2 from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization
Authors: Niesvizky Ruben , Mark Tomer M. , Ward Maureen , Jayabalan David S. , Pearse Roger N. , Manco Megan , Stern Jessica , Christos Paul J. , Mathews Lena , Shore Tsiporah B. , Zafar Faiza , Pekle Karen , Xiang Zhaoying , Ely Scott , Skerret Donna , Chen-Kiang Selina , Coleman Morton , Lane Maureen E.
Published: April 2023

PDF file - 60K, Kaplan-Meier estimates of (A)PFS and (B)OS in patients in the ITT population (N-38).
Supplementary Figure 1 from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization
Authors: Niesvizky Ruben , Mark Tomer M. , Ward Maureen , Jayabalan David S. , Pearse Roger N. , Manco Megan , Stern Jessica , Christos Paul J. , Mathews Lena , Shore Tsiporah B. , Zafar Faiza , Pekle Karen , Xiang Zhaoying , Ely Scott , Skerret Donna , Chen-Kiang Selina , Coleman Morton , Lane Maureen E.
Published: April 2023

PDF file - 58K, Study design and patient flow by intent to treat (ITT).
Supplementary Figure 2 from Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics
Authors: Stacchiotti S. , Tortoreto M. , Bozzi F. , Tamborini E. , Morosi C. , Messina A. , Libertini M. , Palassini E. , Cominetti D. , Negri T. , Gronchi A. , Pilotti S. , Zaffaroni N. , Casali P.G.
Published: April 2023

PDF file, 227K, SFT xenotransplanted in SCID mice pathologic evaluation before and after treatment. A and B Pre-treatment samples: high-grade sarcoma aspects mixed with cartilaginous (A) and osseous component (B). C and D Post-sunitinib, post-bevacizumab and post-pazopanib samples. 120 days after the end of treatment with sunitinib (C), bevacizumab (D) xenografts were sacrificed. The tumor samples were all made of hypercellular viable, mainly spindle tumor cells, intermingled with osteoid matrix. Pazopanib (E) xenograft was instead sacrificed soon after treatment end, Even in this case tumor sample appeared to be completely vital.
Supplementary Figure 1 from Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics
Authors: Stacchiotti S. , Tortoreto M. , Bozzi F. , Tamborini E. , Morosi C. , Messina A. , Libertini M. , Palassini E. , Cominetti D. , Negri T. , Gronchi A. , Pilotti S. , Zaffaroni N. , Casali P.G.
Published: April 2023

PDF file, 256K, A Human primary tumor: morphology (i.e., patternless growth, collagen deposition, moderate cellularity, mitotic index (>4X10 High Power Field (HPF), as shown in panel 1) and immunophenotype (i.e., diffuse positivity for CD34, as shown in panel 1/a) were consistent with a malignant SFT. Immunohistochemistry was positive for PDGFRB expression (panel 1/b). B Human relapsed tumor: morphology was consistent with a dedifferentiated SFT (DSFT), being marked by the abrupt transition from areas with MSFT aspects similar to what observed in the primary tumor (panel 2) to areas with high-grade sarcoma features (panel 3). High-grade areas showed hypercellularity (panel 3/a), chondroid (panel 3/b) and osteoid differentiation (panel 3/c). C Xenograft tumor: morphology was consistent with a high-grade DSFT (panel 4), superimposable to what observed in panel B, 3a/3b/3c, again with presence of mineralized trabeculaes and osteoid (panel 4/a). Immunohistochemistry was positive for PDGFRB expression (panel 4/b). Phospho receptor tyrosine kinase (pRTK) array (ARY001 Proteome ProfilerTM Array, R&D Systems) showed similar profiles for human relapsed tumor (panel B, 3/d) and xenograft (panel C, 4/c) with the activation of PDGFRA (green boxes), PDGFRB (red boxes) and VEGFR1 (yellow boxes). White boxes are the proteome profiler negative controls.
Supplementary Figure 3 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
Authors: Veomett Nicholas , Dao Tao , Liu Hong , Xiang Jingyi , Pankov Dmitry , Dubrovsky Leonid , Whitten Joseph A. , Park Sun-Mi , Korontsvit Tatyana , Zakhaleva Victoria , Casey Emily , Curcio Michael , Kharas Michael G. , O'Reilly Richard J. , Liu Cheng , Scheinberg David A.
Published: April 2023

PDF file - 183KB, (A) ESKM reduced individual tumor burden during the treatment course in 3 of 5 mice. Alternate representation of data in Figure 2A, where signal for each mouse is normalized to starting luminescence. (B) ESKM had no effect against JMN in a NOG mouse model. (C) Comparison of BV173 (Ph+ ALL) and SET2 (AML) cell lines in NSG mice.
Supplementary Table 2 from CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Cancer
Authors: Cleven Arjen H.G. , Derks Sarah , Draht Muriel X.G. , Smits Kim M. , Melotte Veerle , Van Neste Leander , Tournier Benjamin , Jooste Valerie , Chapusot Caroline , Weijenberg Matty P. , Herman James G. , de Bruïne Adriaan P. , van Engeland Manon
Published: April 2023

Epi)genetic alterations in relation to clinicopathological characteristics of the study population.
Supplementary Figure 4 from Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Authors: Skor Maxwell N. , Wonder Erin L. , Kocherginsky Masha , Goyal Anju , Hall Ben A. , Cai Yi , Conzen Suzanne D.
Published: April 2023

Supplementary Figure 4 - PDF file 1452K, Caspase-2 cleavage following treatment with mifepristone
Supplementary Figure 6 from CD133+ Tumor Initiating Cells in a Syngenic Murine Model of Pancreatic Cancer Respond to Minnelide
Authors: Banerjee Sulagna , Nomura Alice , Sangwan Veena , Chugh Rohit , Dudeja Vikas , Vickers Selwyn M. , Saluja Ashok
Published: April 2023

PDF file - 1784KB, Representative slides from tumors treated (B) and untreated (A) with Minnelide.
Supplementary Figure 2 from Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Authors: Skor Maxwell N. , Wonder Erin L. , Kocherginsky Masha , Goyal Anju , Hall Ben A. , Cai Yi , Conzen Suzanne D.
Published: April 2023

Supplementary Figure 2 - PDF file 168K, Phase-contrast and fluorescent images of apoptotic MDA-MB-231 cells
Supplementary Figure 4 from CD133+ Tumor Initiating Cells in a Syngenic Murine Model of Pancreatic Cancer Respond to Minnelide
Authors: Banerjee Sulagna , Nomura Alice , Sangwan Veena , Chugh Rohit , Dudeja Vikas , Vickers Selwyn M. , Saluja Ashok
Published: April 2023

PDF file - 998KB, Immunohistochemistry of tumors.
Supplementary Text from Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation
Authors: Martin Eric S. , Belmont Peter J. , Sinnamon Mark J. , Richard Larissa Georgeon , Yuan Jing , Coffee Erin M. , Roper Jatin , Lee Lydia , Heidari Pedram , Lunt Sophia Y. , Goel Gautam , Ji Xiadong , Xie Zhi , Xie Tao , Lamb John , Weinrich Scott L. , VanArsdale Todd , Bronson Roderick T. , Xavier Ramnik J. , Vander Heiden Matthew G. , Kan Julie L. C. , Mahmood Umar , Hung Kenneth E.
Published: April 2023

PDF file - 151 KB, Supplemental text including supplemental methods, supplemental figure and table legends, and supplemental references.
Supplementary Figure S6 from Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation
Authors: Martin Eric S. , Belmont Peter J. , Sinnamon Mark J. , Richard Larissa Georgeon , Yuan Jing , Coffee Erin M. , Roper Jatin , Lee Lydia , Heidari Pedram , Lunt Sophia Y. , Goel Gautam , Ji Xiadong , Xie Zhi , Xie Tao , Lamb John , Weinrich Scott L. , VanArsdale Todd , Bronson Roderick T. , Xavier Ramnik J. , Vander Heiden Matthew G. , Kan Julie L. C. , Mahmood Umar , Hung Kenneth E.
Published: April 2023

PDF file - 18 KB, Affymetrix probeset gene expression data for GLUT-1 in AP vs AKP cell lines
Supplementary Tables 1 - 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
Authors: Cervantes Andres , Elez Elena , Roda Desamparados , Ecsedy Jeffrey , Macarulla Teresa , Venkatakrishnan Karthik , Roselló Susana , Andreu Jordi , Jung JungAh , Sanchis-Garcia Juan Manuel , Piera Adelaida , Blasco Inma , Maños Laura , Pérez-Fidalgo José-Alejandro , Fingert Howard , Baselga Jose , Tabernero Josep
Published: April 2023

PDF file, 92K, Supplementary Table S1. Summary of pharmacokinetic parameters for MLN8237 once-daily dosing on the 7-day schedule. Supplementary Table S2. Summary of pharmacokinetic parameters for MLN8237 once-daily dosing on the 14-day schedule. Supplementary Table S3. Summary of pharmacokinetic parameters for MLN8237 once-daily dosing on the 21-day schedule. Supplementary Table S4. Summary of pharmacokinetic parameters for MLN8237 twice-daily dosing on the 7-day schedule.
Supplementary Figure S2 from Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation
Authors: Martin Eric S. , Belmont Peter J. , Sinnamon Mark J. , Richard Larissa Georgeon , Yuan Jing , Coffee Erin M. , Roper Jatin , Lee Lydia , Heidari Pedram , Lunt Sophia Y. , Goel Gautam , Ji Xiadong , Xie Zhi , Xie Tao , Lamb John , Weinrich Scott L. , VanArsdale Todd , Bronson Roderick T. , Xavier Ramnik J. , Vander Heiden Matthew G. , Kan Julie L. C. , Mahmood Umar , Hung Kenneth E.
Published: April 2023

PDF file - 215 KB, Orthotopic transplantation of GEMM tumor derived cell lines into the distal colon
Supplementary Figure 2 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
Authors: Cervantes Andres , Elez Elena , Roda Desamparados , Ecsedy Jeffrey , Macarulla Teresa , Venkatakrishnan Karthik , Roselló Susana , Andreu Jordi , Jung JungAh , Sanchis-Garcia Juan Manuel , Piera Adelaida , Blasco Inma , Maños Laura , Pérez-Fidalgo José-Alejandro , Fingert Howard , Baselga Jose , Tabernero Josep
Published: April 2023

PDF file, 2004K, Figure S2. Changes in skin mitotic index on days 7, 14 and 21.
Related Article from Phospho-specific Flow: Fixating on the Target
Authors: Levis Mark
Published: April 2023

Related Article from Phospho-specific Flow: Fixating on the Target
Supplementary Figure 2 from Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines
Authors: Morgillo Floriana , Sasso Ferdinando Carlo , Della Corte Carminia Maria , Vitagliano Donata , D'Aiuto Elena , Troiani Teresa , Martinelli Erika , De Vita Ferdinando , Orditura Michele , De Palma Raffaele , Ciardiello Fortunato
Published: April 2023

Supplementary Figure 2 - PDF file 194K, Supplementary Figure 2. Effects on the downstream pathways by metformin treatment in A549 and H460
Related Article from What's in a Label? Radioimmunotherapy for Metastatic Prostate Cancer
Authors: Simone Charles B. , Hahn Stephen M.
Published: April 2023

Related Article from What's in a Label? Radioimmunotherapy for Metastatic Prostate Cancer
Supplementary Figure 2 from A Targeted RNAi Screen of the Breast Cancer Genome Identifies KIF14 and TLN1 as Genes That Modulate Docetaxel Chemosensitivity in Triple-Negative Breast Cancer
Authors: Singel Stina Mui , Cornelius Crystal , Batten Kimberly , Fasciani Gail , Wright Woodring E. , Lum Lawrence , Shay Jerry W.
Published: April 2023

PDF File - 35K, Annexin V staining by flow cytometry 24 hours after addition of 1nM docetaxel to MDA-MB-231 cells.
Supplementary Figures 1 - 5, Tables 1 - 2 from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
Authors: Garcia Pablo D. , Langowski John L. , Wang Yingyun , Chen Min , Castillo Joseph , Fanton Christie , Ison Marjorie , Zavorotinskaya Tatiana , Dai Yumin , Lu Jing , Niu Xiao-Hong , Basham Stephen , Chan Julie , Yu Jianjun , Doyle Michael , Feucht Paul , Warne Robert , Narberes Jamie , Tsang Tiffany , Fritsch Christine , Kauffmann Audrey , Pfister Estelle , Drueckes Peter , Trappe Joerg , Wilson Christopher , Han Wooseok , Lan Jiong , Nishiguchi Gisele , Lindvall Mika , Bellamacina Cornelia , Aycinena J. Alex , Zang Richard , Holash Jocelyn , Burger Matthew T.
Published: April 2023

PDF file - 346KB, Supplementary Figure 1. Normal vs. Tumor expression of PIM kinases mRNA across 17 tissue types. Supplementary Figure 2. Comparison of LGB321 on-target activity vs. Previously described pan-PIM inhibitor. Supplementary Figure 3. KINOMESCANTM of 1 mu M LGB321. Supplementary Figure 4. Biochemical and cellular selectivity of the LGB321 PIM inhibitor series towards GSK3 beta. Supplementary Figure 5. LGB321 does not inhibit EGFR signaling in HCC1954 cells. Supplementary Table 1. Sensitivity to LGB321 and Erlotinib of Lung Cells in the CCLE. Supplementary Table 2. Sensitivity to LGB321 of hematological malignacies cell lines.
Supplementary Table 5 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
Authors: Radvanyi Laszlo G. , Bernatchez Chantale , Zhang Minying , Fox Patricia S. , Miller Priscilla , Chacon Jessica , Wu Richard , Lizee Gregory , Mahoney Sandy , Alvarado Gladys , Glass Michelle , Johnson Valen E. , McMannis John D. , Shpall Elizabeth , Prieto Victor , Papadopoulos Nicholas , Kim Kevin , Homsi Jade , Bedikian Agop , Hwu Wen-Jen , Patel Sapna , Ross Merrick I. , Lee Jeffrey E. , Gershenwald Jeffrey E. , Lucci Anthony , Royal Richard , Cormier Janice N. , Davies Michael A. , Mansaray Rahmatu , Fulbright Orenthial J. , Toth Christopher , Ramachandran Renjith , Wardell Seth , Gonzalez Audrey , Hwu Patrick
Published: April 2023

PDF file - 77K, Long term changes in the persistence of TCR Vβ clonotypes in the blood following TIL adoptive transfer in representative responding patients
Supplementary Figure 2 from Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer
Authors: Chittaranjan Suganthi , Bortnik Svetlana , Dragowska Wieslawa H. , Xu Jing , Abeysundara Namal , Leung Amy , Go Nancy E. , DeVorkin Lindsay , Weppler Sherry A. , Gelmon Karen , Yapp Donald T. , Bally Marcel B. , Gorski Sharon M.
Published: April 2023

EPI treatment (100-400 nM) results in altered transcript levels of autophagy genes in surviving cells.
Supplementary Material from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
Authors: Dal Pra Alan , Lalonde Emilie , Sykes Jenna , Warde Fiona , Ishkanian Adrian , Meng Alice , Maloff Chad , Srigley John , Joshua Anthony M. , Petrovics Gyorgy , van der Kwast Theodorus , Evans Andrew , Milosevic Michael , Saad Fred , Collins Colin , Squire Jeremy , Lam Wan , Bismar Tarek A. , Boutros Paul C. , Bristow Robert G.
Published: April 2023

Supplementary Material - PDF file 121K, Supplementary figue legends and supplementary tables
Supplementary Figure 6 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
Authors: Dal Pra Alan , Lalonde Emilie , Sykes Jenna , Warde Fiona , Ishkanian Adrian , Meng Alice , Maloff Chad , Srigley John , Joshua Anthony M. , Petrovics Gyorgy , van der Kwast Theodorus , Evans Andrew , Milosevic Michael , Saad Fred , Collins Colin , Squire Jeremy , Lam Wan , Bismar Tarek A. , Boutros Paul C. , Bristow Robert G.
Published: April 2023

Supplementary Figure 6 - PDF file 113K, Univariate Kaplan-Meier plots of bRFR versus time to recurrence for the Memorial Sloan Kettering Prostate Cancer cohort of patients who underwent surgery with differential TMPRSS2-ERG fusion status based on array Comparative Genome Hybridization (aCGH)
Supplementary Figure 3 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
Authors: Dal Pra Alan , Lalonde Emilie , Sykes Jenna , Warde Fiona , Ishkanian Adrian , Meng Alice , Maloff Chad , Srigley John , Joshua Anthony M. , Petrovics Gyorgy , van der Kwast Theodorus , Evans Andrew , Milosevic Michael , Saad Fred , Collins Colin , Squire Jeremy , Lam Wan , Bismar Tarek A. , Boutros Paul C. , Bristow Robert G.
Published: April 2023

Supplementary Figure 3 - PDF file 164K, A) Univariate Kaplan-Meier plots of biochemical relapse-free rates (bRFR) according to PSA levels in the aCGH-cohort. B) Univariate Kaplan-Meier plots of biochemical relapse-free rates (bRFR) according to T-category in the aCGH-cohort. C) Univariate Kaplan-Meier plots of biochemical relapse-free rates (bRFR) according to Gleason score in the aCGH-cohort. D) Univariate Kaplan-Meier plots of biochemical relapse-free rates (bRFR) according PSA levels in the IHC-cohort. E) Univariate Kaplan-Meier plots of biochemical relapse-free rates (bRFR) according to T category in the IHC-cohort. F) Univariate Kaplan-Meier plots of biochemical relapse-free rates (bRFR) according to Gleason score in the IHC-cohort
Data Supplement from An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer
Authors: Noguchi Satoshi , Saito Akira , Horie Masafumi , Mikami Yu , Suzuki Hiroshi I. , Morishita Yasuyuki , Ohshima Mitsuhiro , Abiko Yoshimitsu , Mattsson Johanna Sofia Margareta , König Helena , Lohr Miriam , Edlund Karolina , Botling Johan , Micke Patrick , Nagase Takahide
Published: April 2023

Supplementary Table S1. Sequences of artificial miRNAs against TAZ. Supplementary Table S2. Primers used for quantitative RT-PCR. Supplementary Table S3. Correlation between TAZ gene expression (202134_s_at) and clinicopathological parameters of 196 NSCLC patients included in the Uppsala gene microarray. Supplementary Table S4. Correlation between TAZ protein expression and clinicopathological parameters of 345 NSCLC patients included in the Uppsala tissue microarray. Supplementary Table S5. 259 TAZ-regulated genes commonly upregulated by TAZ overexpression or downregulated by TAZ knockdown in at least two cells out of A549, H441, MCF10A, and SW480 cells.
Supplementary Figure S1 from Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
Authors: Fjeldbo Christina S. , Julin Cathinka H. , Lando Malin , Forsberg Malin F. , Aarnes Eva-Katrine , Alsner Jan , Kristensen Gunnar B. , Malinen Eirik , Lyng Heidi
Published: April 2023

Comparing classification based on ABrix and 6-gene classifier.
Supplementary Table S2 from Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome
Authors: Karlsson Anna , Jönsson Mats , Lauss Martin , Brunnström Hans , Jönsson Per , Borg Åke , Jönsson Göran , Ringnér Markus , Planck Maria , Staaf Johan
Published: April 2023

Supplementary Table S2. Table describing the 4136 CpG set with aberrant methylation in tumors, and the global correlation analysis of DNA methylation and gene expression in lung adenocarcinoma.
Supplementary Table S1 from Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome
Authors: Karlsson Anna , Jönsson Mats , Lauss Martin , Brunnström Hans , Jönsson Per , Borg Åke , Jönsson Göran , Ringnér Markus , Planck Maria , Staaf Johan
Published: April 2023

Supplementary Table S1. Table describing the six identified highly correlated gene expression modules in lung cancer.
supplemental figure legend from Intratumor Heterogeneity in Hepatocellular Carcinoma
Authors: Friemel Juliane , Rechsteiner Markus , Frick Lukas , Böhm Friederike , Struckmann Kirsten , Egger Michèle , Moch Holger , Heikenwalder Mathias , Weber Achim
Published: April 2023

supplemental figure legend
Supplementary table 1 from Intratumor Heterogeneity in Hepatocellular Carcinoma
Authors: Friemel Juliane , Rechsteiner Markus , Frick Lukas , Böhm Friederike , Struckmann Kirsten , Egger Michèle , Moch Holger , Heikenwalder Mathias , Weber Achim
Published: April 2023

Supplementary table 1. Fusion primer sequences
Supplementary figure 4 from Intratumor Heterogeneity in Hepatocellular Carcinoma
Authors: Friemel Juliane , Rechsteiner Markus , Frick Lukas , Böhm Friederike , Struckmann Kirsten , Egger Michèle , Moch Holger , Heikenwalder Mathias , Weber Achim
Published: April 2023

Supplementary figure 4. detailed case description Patient 1 and 22
Supplementary figure 3 from Intratumor Heterogeneity in Hepatocellular Carcinoma
Authors: Friemel Juliane , Rechsteiner Markus , Frick Lukas , Böhm Friederike , Struckmann Kirsten , Egger Michèle , Moch Holger , Heikenwalder Mathias , Weber Achim
Published: April 2023

Supplementary figure 3. CK7 Expression patterns
Supplementary figure 2 from Intratumor Heterogeneity in Hepatocellular Carcinoma
Authors: Friemel Juliane , Rechsteiner Markus , Frick Lukas , Böhm Friederike , Struckmann Kirsten , Egger Michèle , Moch Holger , Heikenwalder Mathias , Weber Achim
Published: April 2023

Supplementary figure 2. Kaplan Meier curves
Supplementary Figure S1 from Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis
Authors: Zhong Qian , Peng Hong-Ling , Zhao Xia , Zhang Lin , Hwang Wei-Ting
Published: April 2023

Supplementary Figure S1. Funnel plots of the meta-analyses assessing the associations between BRCA mutations and survival. (A) Studies about effect of BRCA1 mutation on ovarian cancer OS, (B) Studies about effect of BRCA2 mutation on ovarian cancer OS, (C) Studies about effect of BRCA1 mutation on breast cancer OS, (D) Studies about effect of BRCA1 mutation on breast cancer PFS.
Supplementary Figure Legend from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Authors: Rivera Zeyana , Ferrone Soldano , Wang Xinhui , Jube Sandro , Yang Haining , Pass Harvey I. , Kanodia Shreya , Gaudino Giovanni , Carbone Michele
Published: April 2023

PDF file, 91K.
Supplementary Methods, Figure Legends from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
Authors: Chen Xuanyu , Wang Xuegang , Ruan Anming , Han Weiwei , Zhao Yan , Lu Xing , Xiao Pei , Shi Hangchuan , Wang Rong , Chen Li , Chen Shaoyong , Du Quansheng , Yang Hongmei , Zhang Xiaoping
Published: April 2023

PDF file - 145K
Supplementary Figure 1 from Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab
Authors: Bossi Paolo , Bergamini Cristiana , Siano Marco , Cossu Rocca Maria , Sponghini Andrea P. , Favales Federica , Giannoccaro Marco , Marchesi Edoardo , Cortelazzi Barbara , Perrone Federica , Pilotti Silvana , Locati Laura D. , Licitra Lisa , Canevari Silvana , De Cecco Loris
Published: April 2023

Fig S1. Volcano plot for the 17,378 genes detected by microarray analysis. The x-axis is the fold-change, and the y-axis is log10 p value. A total of 509 probes (blue dots) were differentially expressed in long-PFS patients (14) compared with short-PFS patients (26), imposing a FDR < 15%. Probability of finding by chance 509 significant DE genes between the classes: p = 0.016.
Supplementary Figure 1 from Complete Regression of Metastatic Renal Cell Carcinoma by Multiple Injections of Engineered Mesenchymal Stem Cells Expressing Dodecameric TRAIL and HSV-TK
Authors: Kim Sae Won , Kim Su Jin , Park Sang Hoon , Yang Hyun Gul , Kang Moon Cheol , Choi Young Woo , Kim Seong Muk , Jeun Sin-Soo , Sung Young Chul
Published: April 2023

PDF file - 122K, Phenotype of na�ve and engineered MSCs
supplementary Figure 1 from Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
Authors: Hu Bo , Yang Xin-Rong , Xu Yang , Sun Yun-Fan , Sun Chao , Guo Wei , Zhang Xin , Wang Wei-Min , Qiu Shuang-Jian , Zhou Jian , Fan Jia
Published: April 2023

Supplementary figure S1. The optimal cutoff value for the SII was selected by X-tile 3.6.1 software (Yale University, New Haven, CT, USA).
Data Supplement from Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
Authors: Seiwert Tanguy Y. , Zuo Zhixiang , Keck Michaela K. , Khattri Arun , Pedamallu Chandra S. , Stricker Thomas , Brown Christopher , Pugh Trevor J. , Stojanov Petar , Cho Juok , Lawrence Michael S. , Getz Gad , Brägelmann Johannes , DeBoer Rebecca , Weichselbaum Ralph R. , Langerman Alexander , Portugal Louis , Blair Elizabeth , Stenson Kerstin , Lingen Mark W. , Cohen Ezra E.W. , Vokes Everett E. , White Kevin P. , Hammerman Peter S.
Published: April 2023

Description of additional methodology that is not part of manuscript including: Sample preparation and DNA purification, HPV PCR and HPV consensus testing, Library preparation and target capture, CN aberration/Nanostring, Sequencing data analysis and Statistical analysis.
Suppl Fig S4 from Complement Pathway Is Frequently Altered in Endometriosis and Endometriosis-Associated Ovarian Cancer
Authors: Suryawanshi Swati , Huang Xin , Elishaev Esther , Budiu Raluca A. , Zhang Lixin , Kim SungHwan , Donnellan Nicole , Mantia-Smaldone Gina , Ma Tianzhou , Tseng George , Lee Ted , Mansuria Suketu , Edwards Robert P. , Vlad Anda M.
Published: April 2023

Suppl Fig S4. Complement and non-target siRNA
Data Supplement from Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
Authors: Seiwert Tanguy Y. , Zuo Zhixiang , Keck Michaela K. , Khattri Arun , Pedamallu Chandra S. , Stricker Thomas , Brown Christopher , Pugh Trevor J. , Stojanov Petar , Cho Juok , Lawrence Michael S. , Getz Gad , Brägelmann Johannes , DeBoer Rebecca , Weichselbaum Ralph R. , Langerman Alexander , Portugal Louis , Blair Elizabeth , Stenson Kerstin , Lingen Mark W. , Cohen Ezra E.W. , Vokes Everett E. , White Kevin P. , Hammerman Peter S.
Published: April 2023

Supplementary Figure S2. Selection of mutated genes sorted by HPV association (q-values). Histogram shows percentage of cases with mutations occurring in HPV(-) and HPV(+) samples.
Data Supplement from Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
Authors: Seiwert Tanguy Y. , Zuo Zhixiang , Keck Michaela K. , Khattri Arun , Pedamallu Chandra S. , Stricker Thomas , Brown Christopher , Pugh Trevor J. , Stojanov Petar , Cho Juok , Lawrence Michael S. , Getz Gad , Brägelmann Johannes , DeBoer Rebecca , Weichselbaum Ralph R. , Langerman Alexander , Portugal Louis , Blair Elizabeth , Stenson Kerstin , Lingen Mark W. , Cohen Ezra E.W. , Vokes Everett E. , White Kevin P. , Hammerman Peter S.
Published: April 2023

Supplementary Table S1. List of genes and significant copy number changes. (A) List of genes included in the sequencing analysis/capture, (B) Validation rate by variant class, (C) Validation rate by gene (D) Significant copy number gain in HPV negative, (E) Significant copy number loss in HPV negative, (F) Significant copy number gain in HPV positive, (G) Significant copy number loss in HPV positive (H) Validation of significant copy number changes.
Supplementary Figure 4 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Authors: Psyrri Amanda , Lee Ju-Whei , Pectasides Eirini , Vassilakopoulou Maria , Kosmidis Efstratios K. , Burtness Barbara A. , Rimm David L. , Wanebo Harold J. , Forastiere Arlene A.
Published: April 2023

PDF file - 55K, Kaplan-Meier estimates of (a) overall survival, (b) progression-free survival by NRAS and ERK cluster status.
Supplementary Figure 2 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Authors: Psyrri Amanda , Lee Ju-Whei , Pectasides Eirini , Vassilakopoulou Maria , Kosmidis Efstratios K. , Burtness Barbara A. , Rimm David L. , Wanebo Harold J. , Forastiere Arlene A.
Published: April 2023

PDF file - 61K, Kaplan-Meier estimates of (a) overall survival, (b) progression-free survival by PIK3CA, NRAS, and PTEN cluster status.
Data Supplement from Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
Authors: Gupta Shiv K. , Mladek Ann C. , Carlson Brett L. , Boakye-Agyeman Felix , Bakken Katrina K. , Kizilbash Sani H. , Schroeder Mark A. , Reid Joel , Sarkaria Jann N.
Published: April 2023

Supplementary Material. Methods for analysis of apoptosis & pluripotency; and Figure Legends to the Supplementary Figures
Supplementary Figure S1 from CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
Authors: Lee Yunqin , Shin June Ho , Longmire Michelle , Wang Hua , Kohrt Holbrook E. , Chang Howard Y. , Sunwoo John B.
Published: April 2023

Supplementary Figure S1. Gating strategy for isolating tumor cells from primary SCCHN tumors and xenografts.
Supplemental Material from A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors
Authors: Dowlati Afshin , Vlahovic Gordana , Natale Ronald B. , Rasmussen Erik , Singh Indrajeet , Hwang Yuying C. , Rossi John , Bass Michael B. , Friberg Gregory , Pickett Cheryl A.
Published: April 2023

Supplemental Table 1 (Patient Incidence of Treatment-Related Adverse Events) and Supplemental Figure 1 (AMG 780 dose cohorts and patient enrollment)
Supplemental Materials and Methods from Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression
Authors: Chang Te-Sheng , Wu Yu-Chih , Chi Ching-Chi , Su Wei-Chi , Chang Pey-Jium , Lee Kam-Fai , Tung Tao-Hsin , Wang Jui , Liu Jun-Jen , Tung Shui-Yi , Kuo Liang-Mou , Ho Hong-Nerng , Ling Thai-Yen , Huang Yen-Hua
Published: April 2023

Supplemental Materials and Methods
Supplementary Figure Legends from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma
Authors: Radon Tomasz P. , Massat Nathalie J. , Jones Richard , Alrawashdeh Wasfi , Dumartin Laurent , Ennis Darren , Duffy Stephen W. , Kocher Hemant M. , Pereira Stephen P. , Guarner (posthumous) Luisa , Murta-Nascimento Cristiane , Real Francisco X. , Malats Núria , Neoptolemos John , Costello Eithne , Greenhalf William , Lemoine Nick R. , Crnogorac-Jurcevic Tatjana
Published: April 2023

Supplementary Figure Legends from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma
Supplementary Figure 6 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma
Authors: Radon Tomasz P. , Massat Nathalie J. , Jones Richard , Alrawashdeh Wasfi , Dumartin Laurent , Ennis Darren , Duffy Stephen W. , Kocher Hemant M. , Pereira Stephen P. , Guarner (posthumous) Luisa , Murta-Nascimento Cristiane , Real Francisco X. , Malats Núria , Neoptolemos John , Costello Eithne , Greenhalf William , Lemoine Nick R. , Crnogorac-Jurcevic Tatjana
Published: April 2023

Expression of the protein biomarkers in pancreatic cancer tissues. A, Immunohistochemical analysis of REG1A: i) REG1A in poorly differentiated PDAC, ii) luminal REG1A in malignant glands. B, TFF1: i) heterogenous expression in cancer,, ii) luminal TFF1 in malignant gland. C, LYVE1 expression in the scattered lymphatic vessels i) in the muscle layer and ii) in the stroma surrounding malignant gland. D, The biomarker levels during monitoring of pancreatic adenocarcinoma patients: LYVE1, REG1A and TFF1 were measured using ELISA in urine samples collected before surgery and during the patient's follow up. Each point represents log-transformed ELISA values at a particular time point (x-axis).
Supplementary Figure 5 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma
Authors: Radon Tomasz P. , Massat Nathalie J. , Jones Richard , Alrawashdeh Wasfi , Dumartin Laurent , Ennis Darren , Duffy Stephen W. , Kocher Hemant M. , Pereira Stephen P. , Guarner (posthumous) Luisa , Murta-Nascimento Cristiane , Real Francisco X. , Malats Núria , Neoptolemos John , Costello Eithne , Greenhalf William , Lemoine Nick R. , Crnogorac-Jurcevic Tatjana
Published: April 2023

Urine biomarker concentrations in different tumours. Scatter dot plots of urine LYVE1, REG1A and plasma CA19.9 in different hepatobiliary pathologies and early stages of pancreatic adenocarcinoma (I-IIA, n=16) and I-II (n=71). The level of TFF1 protein was not measured in these samples due to substantial modifications made to the original ELISA assay by the source company at the moment of this analysis. IPMN (n=33): intraductal papillary mucinous neoplasm, AMP (n=26): ampullary cancer, NET (n=18): neuroendocrine tumour, CHL (n=24): cholangiocarcinoma, DuCA (n=16): duodenal cancer. Bars indicate median and IQR values. Upper bars: Kruskal-Wallis/Dunn's post test, *: p<0.05, **: p<0.01, ***: p<0.001; where not shown, p>0.05 (no adjustment for multiplicity was made).
Data Supplement from Squamous Cell Carcinoma of the Oral Tongue in Young Non-Smokers Is Genomically Similar to Tumors in Older Smokers
Authors: Pickering Curtis R. , Zhang Jiexin , Neskey David M. , Zhao Mei , Jasser Samar A. , Wang Jiping , Ward Alexandra , Tsai C. Jillian , Ortega Alves Marcus V. , Zhou Jane H. , Drummond Jennifer , El-Naggar Adel K. , Gibbs Richard , Weinstein John N. , Wheeler David A. , Wang Jing , Frederick Mitchell J. , Myers Jeffrey N.
Published: April 2023

Supplementary Table 2. Mutation frequencies in select subsets.
Supplementary Figure 3 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma
Authors: Radon Tomasz P. , Massat Nathalie J. , Jones Richard , Alrawashdeh Wasfi , Dumartin Laurent , Ennis Darren , Duffy Stephen W. , Kocher Hemant M. , Pereira Stephen P. , Guarner (posthumous) Luisa , Murta-Nascimento Cristiane , Real Francisco X. , Malats Núria , Neoptolemos John , Costello Eithne , Greenhalf William , Lemoine Nick R. , Crnogorac-Jurcevic Tatjana
Published: April 2023

Diagnostic performance of urine biomarkers in discriminating pancreatic adenocarcinoma all stages (A-C) and stage I-II (D-F) from chronic pancreatitis patients. A, ROC curves of PDAC (n=143) versus CP (n=62) patients for individual urine biomarkers in the training set (70% of the data). B, ROC curves of PDAC versus CP patients for the panel in the training set and in the independent validation set (30% of the data, PDAC n=49, CP n=30). C, Summary table. D, ROC curves of individual urine biomarkers in training dataset (70%, PDAC stage I-II n= 56, CP=66). E, ROC curves of the panel in training and validation (PDAC stage I-II n=15, CP n=26) dataset. F, Summary table. Cnorm, creatinine-normalised, creat, creatinine, AUC: area under the curve SN: sensitivity, SP: specificity with 95% Confidence Interval (CI). SN and SP in the validation set were derived for optimal cutpoint determined in the training dataset.
Supplementary Figure Legend from Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors
Authors: Endo Makoto , Yamamoto Hidetaka , Setsu Nokitaka , Kohashi Kenichi , Takahashi Yusuke , Ishii Takeaki , Iida Kei-ichiro , Matsumoto Yoshihiro , Hakozaki Michiyuki , Aoki Mikiko , Iwasaki Hiroshi , Dobashi Yoh , Nishiyama Kenichi , Iwamoto Yukihide , Oda Yoshinao
Published: April 2023

PDF file - 72K
Supplementary Figure 3 from Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo
Authors: Dibra Denada , Mitra Abhisek , Newman Melisa , Xia Xueqing , Cutrera Jeffry J. , Gagea Mihai , Kleinerman Eugenie S. , Lozano Guillermina , Li Shulin
Published: April 2023

Supplementary Figure 3: Recombinant IL27 induces proliferation and invasion but not migration in-vitro in an osteosarcoma cell line.
Supplementary Figure 4 from Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors
Authors: Endo Makoto , Yamamoto Hidetaka , Setsu Nokitaka , Kohashi Kenichi , Takahashi Yusuke , Ishii Takeaki , Iida Kei-ichiro , Matsumoto Yoshihiro , Hakozaki Michiyuki , Aoki Mikiko , Iwasaki Hiroshi , Dobashi Yoh , Nishiyama Kenichi , Iwamoto Yukihide , Oda Yoshinao
Published: April 2023

PDF file - 385K, Everolimus-induced change in the activation status of the AKT/mTOR and MAPK pathways evaluated by Western blotting. Decreased p-S6RP and p-p70S6K expressions by Everolimus (30 nM, a dose achievable in humans by oral administration) are observed in all MPNST cell lines. p-AKT, p-mTOR, p-MEK, and p-ERK1/2 expressions show no obvious differences between Everolimus administration and no administration. Actin is loaded as a loading control.
Supplementary Figure 3 from Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors
Authors: Endo Makoto , Yamamoto Hidetaka , Setsu Nokitaka , Kohashi Kenichi , Takahashi Yusuke , Ishii Takeaki , Iida Kei-ichiro , Matsumoto Yoshihiro , Hakozaki Michiyuki , Aoki Mikiko , Iwasaki Hiroshi , Dobashi Yoh , Nishiyama Kenichi , Iwamoto Yukihide , Oda Yoshinao
Published: April 2023

PDF file - 182K, The Kaplan-Meier curves for overall survival according to p-p70S6K, p-4E-BP1, p-MEK1/2, and p-ERK1/2 expressions. Immunoreactivity for p-p70S6K, p-4E-BP1, p-MEK1/2, and p-ERK1/2 fails to show a significant difference in overall survival. p values are shown at the top right of each figure.
Supplementary Figure 1 from Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo
Authors: Dibra Denada , Mitra Abhisek , Newman Melisa , Xia Xueqing , Cutrera Jeffry J. , Gagea Mihai , Kleinerman Eugenie S. , Lozano Guillermina , Li Shulin
Published: April 2023

Supplementary Figure 1: Table showing tumor spectrum in IL27RA-/- p53R172H/+ mice.
Supp Figure 1: Cutoff Finder analysis. from Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Authors: Loibl Sibylle , Darb-Esfahani Silvia , Huober Jens , Klimowicz Alexander , Furlanetto Jenny , Lederer Bianca , Hartmann Arndt , Eidtmann Holger , Pfitzner Berit , Fasching Peter A. , Tiemann Katharina , Jackisch Christian , Mehta Keyur , von Minckwitz Gunter , Untch Michael , Denkert Carsten
Published: April 2023

(A) OR were plotted against all possible cutoff points: the range of significant cutoffs was 39.4% with an optimal cutoff at 60.1 immunofluorescence expression values (vertical line). Dotted lines: 95% confidence interval (B) Waterfall plot showing correct and wrong classification of cases in accordance to pCR depending on PTEN immunofluorescence expression.
Supplementary Table 1 from Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
Authors: Roberts Patrick J. , Usary Jerry E. , Darr David B. , Dillon Patrick M. , Pfefferle Adam D. , Whittle Martin C. , Duncan James S. , Johnson Soren M. , Combest Austin J. , Jin Jian , Zamboni William C. , Johnson Gary L. , Perou Charles M. , Sharpless Norman E.
Published: April 2023

PDF file, 53K, MP1U Dosing Regimens.
Supplementary Tables 1 - 5, Figures 1 - 2 from Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel
Authors: Abraham Jean E. , Guo Qi , Dorling Leila , Tyrer Jonathan , Ingle Susan , Hardy Richard , Vallier Anne-Laure , Hiller Louise , Burns Russell , Jones Linda , Bowden Sarah J. , Dunn Janet A. , Poole Christopher J. , Caldas Carlos , Pharoah Paul P.D. , Earl Helena M.
Published: April 2023

PDF file - 237KB, Supplementary Table 1: Published Studies of Putative Functional SNPs Supplementary Table 2a: Drug Regimens and Doses of Taxanes by Study Supplementary Table 2b: Comparison of Toxicity grades/rates by recruiting trial in PGSNPS included in Taxane Related Sensory Neuropathy Study Supplementary Table 3: PGSNPS Taxane Treated Patient Characteristics Supplementary Table 4: All Putative Functional SNPs Replicated in the PGSNPS dataset (phenotype: cumulative dose to TRSN) Supplementary Table 5: All Putative Functional SNPs Replicated in the PGSNPS dataset (phenotype: maximum TRSN) Supplementary Figure 1: Percentage of Patients with TRSN ≥ grade 2 by genotype, for three statistically significant SNPs that were genotyped in PGSNPS (maximum TRSN) Supplementary Figures 2a-c: Kaplan-Meier curves Kaplan-Meier curves: Shows for each SNP, by genotype, the probability of TRSN grade 0-1 (i.e., the probability of not experiencing moderate/severe TRSN) as the cumulative dose increases.
Supplementary Figure 3 from Prospero Homeobox 1 Promotes Epithelial–Mesenchymal Transition in Colon Cancer Cells by Inhibiting E-cadherin via miR-9
Authors: Lu Mei-Hsuan , Huang Chao-Cheng , Pan Mei-Ren , Chen Hong-Hwa , Hung Wen-Chun
Published: April 2023

PDF file - 341K, Typical pictures of IHC double staining of PROX1
Supplementary Figure 3 from Calreticulin Promotes Migration and Invasion of Esophageal Cancer Cells by Upregulating Neuropilin-1 Expression via STAT5A
Authors: Shi Feng , Shang Li , Pan Bei-Qing , Wang Xiao-Min , Jiang Yan-Yi , Hao Jia-Jie , Zhang Yu , Cai Yan , Xu Xin , Zhan Qi-Min , Wang Ming-Rong
Published: April 2023

Supplementary Figure 3. Western blot analysis in ESCC cells treated with or without 100 μmol/L KN-93 for 24 hours.
Supplementary Figure 1 from Calreticulin Promotes Migration and Invasion of Esophageal Cancer Cells by Upregulating Neuropilin-1 Expression via STAT5A
Authors: Shi Feng , Shang Li , Pan Bei-Qing , Wang Xiao-Min , Jiang Yan-Yi , Hao Jia-Jie , Zhang Yu , Cai Yan , Xu Xin , Zhan Qi-Min , Wang Ming-Rong
Published: April 2023

Supplementary Figure 1. Quantitative real-time PCR analysis of CRT expression in ESCC cells transiently transfected with non-silencing siRNA or CRT siRNA. Columns, mean; Bars, SD (n = 3); **, P < 0.01.
Supplementary Table 1 and Figures 1 - 6 from Genome-Wide Association Study of Prognosis in Advanced Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy
Authors: Hu Lingmin , Wu Chen , Zhao Xueying , Heist Rebecca , Su Li , Zhao Yang , Han Baohui , Cao Songyu , Chu Minjie , Dai Juncheng , Dong Jing , Shu Yongqian , Xu Lin , Chen Yijiang , Wang Yi , Lu Feng , Jiang Yue , Yu Dianke , Chen Hongyan , Tan Wen , Ma Hongxia , Chen Jiaping , Jin Guangfu , Wu Tangchun , Lu Daru , Christiani David C. , Lin Dongxin , Hu Zhibin , Shen Hongbing
Published: April 2023

PDF file, 994K, Supplementary Table 1.Result for 33 selected SNPs in discovery studies Supplementary Figure 1. Forest plot represent the effect of the five identified marker SNPs on NSCLC overall survival among different subgroups in all subjects. I2 and P values are from heterogeneity tests. Supplementary Figure 2. Forest plots represent the effect of the five identified marker SNPs (rs7629386 at 3p22.1, rs969088 at 5p14.1, rs41997 at 7q31.31, rs12000445 at 9p21.3 and rs3850370 at 14q24.3) on NSCLC overall survival among different subgroups in all Chinese. I2 and P values are from heterogeneity tests; SCC: squamous cell carcinoma; AC: adenocarcinoma. Supplementary Figure 3. Kaplan-Meier plots of survival for NSCLC by rs7629386. (A) Nanjing discovery set ; (B) Beijing discovery set ; (C) Replication I ; (D) Replication II. Supplementary Figure 4. Kaplan-Meier plots of survival for NSCLC by rs3850370. (A) Nanjing discovery set ; (B) Beijing discovery set ; (C) Replication I ; (D) Replication II. Supplementary Figure 5. Regional plots of ra1878022 and rs10937823 in our GWA scan. Results (−log10 P) are shown in the region flanking 1200 kb on either side of the marker SNPs. The marker SNPs were shown in purple diamond and the R2 values of the rest of the SNPs are indicated by different colors. Supplementary Figure 6. Regional plot of the five identified marker SNPs in 535 Han Chinese with GWAS scan. Results (−log10 P) are shown in the region flanking 1200 kb on either side of the marker SNPs (1000 kb around rs2109664). The marker SNPs were shown in purple diamond and the R2 values of the rest of the SNPs are indicated by different colors. (A) Chr3: rs7629386 (C>T); (B) Chr5: rs969088 (G>C); (C) Chr7: rs41997 (A>G); (D) Chr9: rs12000445 (A>G); (E) Chr14: rs3850370 (A>C).
Supplemental Figure Legend from A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Authors: Reiss Kim A. , Herman Joseph M. , Zahurak Marianna , Brade Anthony , Dawson Laura A. , Scardina Angela , Joffe Caitlin , Petito Emily , Hacker-Prietz Amy , Kinders Robert J. , Wang Lihua , Chen Alice , Temkin Sarah , Horiba Naomi , Siu Lillian L. , Azad Nilofer S.
Published: April 2023

Supplemental Figure Legend from A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Supplemental Table S1. from A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
Authors: Messersmith Wells A. , Shapiro Geoffrey I. , Cleary James M. , Jimeno Antonio , Dasari Arvind , Huang Bo , Shaik M. Naveed , Cesari Rossano , Zheng Xianxian , Reynolds Jennifer M. , English Patricia A. , McLachlan Karen R. , Kern Kenneth A. , LoRusso Patricia M.
Published: April 2023

Supplemental Table S1. Tumor responses to single-agent treatment with PF-03084014 in patients with advanced solid malignancies.
Supplementary figure 4 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy
Authors: Feng Liang , Yao Hang-Ping , Wang Wei , Zhou Yong-Qing , Zhou Jianwei , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

Supplementary figure 4. Effect of anti-RON ADCs Zt/g4-DM1 and Zt/c1-DM1 in vitro on reduction of the number of viable CRC cells
Supplementary figure 2 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy
Authors: Feng Liang , Yao Hang-Ping , Wang Wei , Zhou Yong-Qing , Zhou Jianwei , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

Supplementary figure 2. Effect of anti-RON ADCs in vitro on reduction of viability of CRC cells expressing no or low levels of RON